



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

FEB 15 2011

Re: VPRIV
Docket No.: FDA-2010-E-0400

The Honorable David J. Kappos
Undersecretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the application for patent term extension for U.S. Patent No. 7,138,262, filed by Shire Human Genetic Therapies, Inc., under 35 U.S.C. section 156 et seq. We have reviewed the dates contained in the application and have determined the regulatory review period for VPRIV (velaglucerase alfa), the human drug product claimed by the patent.

The total length of the regulatory review period for VPRIV (velaglucerase alfa) is 2,221 days. Of this time, 2,041 days occurred during the testing phase and 180 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under subsection 505(i) of the Federal Food, Drug, and Cosmetic Act involving this drug product became effective: January 30, 2004.

The applicant claims May 20, 2004, as the date the investigational new drug application (IND) became effective. However, FDA records indicate that the IND effective date was January 30, 2004, which was 30 days after FDA receipt of the IND.

2. The date the application was initially submitted with respect to the human drug product under section 505 of the Federal Food, Drug, and Cosmetic Act: August 31, 2009.

FDA has verified the applicant's claim that the new drug application (NDA) for VPRIV (NDA 22-575) was submitted on August 31, 2009.


3. The date the application was approved: February 26, 2010.

FDA has verified the applicant's claim that NDA 22-575 was approved on February 26, 2010.

This determination of the regulatory review period by FDA does not take into account the effective date of the patent, nor does it exclude one-half of the testing phase as required by 35 U.S.C. section 156(c)(2).

Please let me know if we can be of further assistance.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Jane A. Axelrad". The signature is fluid and cursive, with the first name "Jane" being the most prominent.

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Laurie Butler Lawrence
Lando & Anastasi, LLP
One Main Street
Cambridge, MA 02142